A5083259909- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Radiopharmaceutical Chemistry and Applications
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Dental Education, Practice, Research
- Chronic Myeloid Leukemia Treatments
- Immune cells in cancer
- Immunotherapy and Immune Responses
- BRCA gene mutations in cancer
- Perfectionism, Procrastination, Anxiety Studies
- Cancer Genomics and Diagnostics
- Healthcare professionals’ stress and burnout
- Genetic factors in colorectal cancer
- Medical Imaging Techniques and Applications
- Receptor Mechanisms and Signaling
- Bone health and treatments
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- DNA Repair Mechanisms
- Personality Traits and Psychology
- Anesthesia and Pain Management
- Urologic and reproductive health conditions
British Dental Association
2022-2025
Dana-Farber Cancer Institute
2020-2024
Rosalind Franklin University of Medicine and Science
2024
HiFiBiO Therapeutics (United States)
2021-2022
Harvard University
2021
Cornell University
2019
Memorial Sloan Kettering Cancer Center
1990
St Thomas' Hospital
1985
Abstract Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response immune checkpoint inhibitors 1 . Cellular programs driving in both cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced cancer, spanning all common metastatic sites. Irrespective of treatment exposure, adenocarcinoma pervasively coexpressed multiple...
PURPOSE Nearly all men with prostate cancer treated androgen receptor (AR) signaling inhibitors (ARSIs) develop resistance via diverse mechanisms including constitutive activation of the AR pathway, driven by genomic structural alterations, expression splice variants (AR-Vs), or loss dependence and lineage plasticity termed neuroendocrine cancer. Understanding these de novo acquired ARSI is critical for optimizing therapy. MATERIALS AND METHODS A novel liquid biopsy technology was used to...
We report on the post-radical prostatectomy outcomes of patients enrolled in 3 randomized, multicenter, clinical trials intense neoadjuvant androgen deprivation therapy prior radical prostatectomy.All included were evaluating followed by prostatectomy. The primary end point was time to biochemical recurrence, defined as from prostate specific antigen >0.1 ng/ml or start first therapy, stratified pathological response at (presence absence exceptional residual tumor measuring 0-5 mm)....
Guidelines recommend somatic and germline testing for men with advanced prostate cancer (PCa). Barriers to widespread implementation result in underutilization of testing. Somatic alone risks missing pathogenic variants (PGVs). We sought determine whether the addition tumor-only sequencing improves detection PGVs PCa. Secondarily, we define added value combining optimize clinically actionable alterations.We analyzed results independent from 100 PCa a prospective clinical trial...
Abstract Treatment-induced tumor dormancy is a state in cancer progression where residual disease present but remains asymptomatic. Dormant cells are treatment-resistant and responsible for recurrence metastasis. Prostate treated with androgen-deprivation therapy (ADT) often enters dormant state. ADT-induced prostate poorly understood due to the challenge acquiring clinical lack of representative models. In this study, we aimed develop clinically relevant models studying dormancy. were...
Abstract Background Guidelines for optimal sequencing of radium-223 and chemotherapy metastatic castration resistant prostate cancer (mCRPC) do not exist. This study evaluated treatment patterns overall survival (OS) among patients with mCRPC treated in an academic clinical setting. Methods A retrospective was conducted bone metastases-predominant radium-223. Treatment from 2013 to 2018 were pre- vs. post-chemotherapy. OS examined using Kaplan–Meier medians 95% confidence intervals. Results...
Immune checkpoint inhibitors (ICIs) have limited efficacy in prostate cancer (PCa). Better biomarkers are needed to predict responses ICIs. We sought demonstrate that a panel-based mutational signature identifies mismatch repair (MMR) deficient (MMRd) PCa and is biomarker of response pembrolizumab. Clinico-genomic data was obtained for 2664 patients with sequenced at Dana-Farber Cancer Institute (DFCI) Memorial Sloan Kettering (MSK). Clinical outcomes were collected metastatic...
Germline genetic testing (GT) is recommended for men with prostate cancer (PC), but through traditional models limited. The ProGen study examined a novel model aimed at providing access to GT while promoting education and informed consent.
1507 Background: Approximately 10% of men with advanced prostate cancer (PC) have pathogenic/likely pathogenic variants (PV) in susceptibility genes and their identification may lead to targeted therapy. Genetic testing (GT) can also guide surveillance prevention for family members. While GT is recommended potentially lethal PC, traditional models are strained, access limited. The ProGen study examined a novel pretest model aimed at providing while promoting informed consent. Methods:...
Abstract Despite the success of immune check point inhibition, identification other pathways capable modulating response against tumor remains challenging. T-cell co-stimulation has been investigated with limited clinical so far due in part to fine tuning required for agonist antibodies those co-stimulatory receptors and lack biomarkers facilitate selection patients likely benefit from co-stimulation. TNFR2 belongs TNFR family costimulatory molecules, its expression on infiltrating...
43 Background: PARP inhibitors (PARPi) and platinum chemotherapy cause synthetic lethality result in clinical benefit men with mCRPC whose tumors harbor deleterious alterations DDR genes. BRCA2 is the strongest predictor, but data supports a role for BRCA1, ATM, other PARPi are more expensive than chemotherapy; whether they effective not known. We evaluated outcomes DDR-deficient treated or chemotherapy. Methods: identified at Dana-Farber Cancer Institute who received olaparib carboplatin...
Background: Information on the molecular and phenotypic correlates of acute myeloid leukemia secondary (S-AML) to post-polycythemia vera (post-PV) post-essential thrombocythemia (post-ET) myelofibrosis (known as myelofibrosis, SMF) is scant. Aims: The primary objective this study assess incidence outcome S-AML in a large cohort SMF. To find out predictors occurrence, we performed whole investigation risk factors at time SMF, also applying established prognostic models. Methods: MYSEC...
hen you hear the words social media, what do automatically think of?Instagram?LinkedIn?TikTok?Facebook?Or showing your age, Myspace?Now, holding that thought in head, is it a professional page or personal of?Do have separate and accounts are happy to keep everything under name?Now you've of those questions, ask yourself this: curate posts?By this I mean posted filtered?Do only post Rebecca Silver 1 asks: 'Have we become so paranoid about being "perfect" media age aren't willing learn, grow...
Abstract Background The PARP inhibitor (PARPi) olaparib is approved for homologous recombination repair (HRR) gene‐altered metastatic castration‐resistant prostate cancer (mCRPC). However, there significant heterogeneity in response to PARPi patients with mCRPC. Better clinical biomarkers are needed identify likely benefit from PARPi. Methods Patients adenocarcinoma and panel sequencing at Dana‐Farber Cancer Institute were identified. Mutational signature analysis was performed using SigMA...
Introduction: Intestinal malrotation and duplication are rare congenital anomalies that typically present in childhood, but can also occur adults. Adult presentations often associated with acute obstructive symptoms, complications like volvulus ischemia rapidly lead to life-threatening outcomes. Early recognition intervention essential for ensuring favorable Case Report: We report an interesting case of intestinal a 49-year-old male who presented abdominal pain, bilious vomiting, bloating....
Abstract A method has been developed for simultaneously comparing the usefulness of many treatments established value symptomatic medical conditions. Medical assessment outcome is not employed. Instead patients are required to assess prescribed during course ordinary general practice rather than under strictly controlled settings most clinical trials. Outcome incorporates patient compliance and treatment acceptability based on patients' subjective judgements randomly allocated as recorded in...
223 Background: Guidelines for optimal sequencing of approved mCRPC therapies do not exist. This study evaluated treatment patterns and overall survival (OS) among patients (pts) with treated Ra-223 in an academic clinical setting. Methods: A retrospective chart review was conducted at Dana-Farber Cancer Institute bone metastases-predominant pts Ra-223. Treatment from 2013-2018 were including initiation pre- vs. post-chemotherapy (chemo). OS examined using Kaplan-Meier medians 95% confidence...
Abstract The discovery of predictive biomarkers response is critical for forecasting patient benefit from novel immune-modulatory therapeutics. However, their hindered by the complexity drug modes action and lack adequate biological models. We designed an approach to define subjecting dissociated tissue human tumors T cell-targeting biologics or combinations, followed single-cell transcriptomic profiling TCR clonotype characterization. Responding cells are identified as those showing...
Abstract Agonist OX40 antibodies have shown promising pre-clinical activities, but their clinical activities been limited thus far. Several reasons may account for this activity, including sub-optimal antibody design, dose selection, and lack of a biomarker strategy indication selection patient enrichment. Previous trials selected doses that maximized receptor occupancy, some patients responded at lower doses, indicating nuances to choosing the correct therapeutic an agonist antibody. In...